Oncotelic Therapeutics Inc Stock Price, News & Analysis

Oncotelic Therapeutics (OTLC) announced the development of OT-101, its RNA therapeutic targeting TGF-β, which has shown good efficacy in over six clinical trials against solid tumors. Currently, OT-101 is in a phase 1b trial combined with IL-2 and is being tested alongside pembrolizumab in multiple trials. The company is set to present its immunotherapy pipeline at BiotechGate Digital Partnering from Feb 7-11, 2022, aiming for transformative outcomes in treating high-TGF solid tumors. OT-101 has also shown efficacy against COVID-19 in a completed phase 2 trial.

Oncotelic Therapeutics (OTCQB:OTLC) has submitted a clinical study protocol to the US FDA for a Phase 1 trial of CA4P combined with pembrolizumab for melanoma treatment. This multicenter, open-label study aims to assess the safety and initial efficacy of CA4P in patients with recurrent metastatic melanoma. CA4P has been previously evaluated in over 500 patients across 17 studies. The trial leverages CA4P's potential synergy with checkpoint inhibitors and seeks to gain marketing approval for CA4P in a Rare Pediatric Disease.

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) has announced a significant finding in its analysis of SARS-CoV-2, identifying the open reading frame 8 (ORF8) as a critical factor in the evolution of Delta and Omicron variants. The study revealed that higher serum levels of ORF8 in COVID-19 patients correlate with increased fatality rates. The company aims to leverage this information to develop therapeutics and vaccines targeting ORF8 as the virus mutates further. This analysis indicates an urgent need for ongoing innovation in COVID-19 treatment strategies.

Oncotelic Therapeutics (OTCQB:OTLC) announced that Dr. Anthony Maida will present at the 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit from January 25-27, 2022. The summit will showcase TGF-β inhibitors' potential in oncology and virology, particularly OT-101. This first-in-class anti-TGF-β RNA therapeutic has shown promise against relapsed cancer and is currently under evaluation for severe COVID-19 cases. Oncotelic aims to enhance treatment outcomes for cancer, emphasizing rare pediatric conditions.

Oncotelic Therapeutics (OTCQB:OTLC) has submitted a clinical study protocol to the US FDA for a Phase 2 trial (M201) of OT-101, its TGF-β inhibitor, combined with Anti-PD-1 (Pembrolizumab) for treating Malignant Pleural Mesothelioma (MPM). OT-101 is a first-in-class RNA therapeutic showing efficacy in cancer and has demonstrated activity against the SARS-CoV-2 virus. The trial aims to assess TGF-β inhibition's impact on various solid tumors while evaluating changes in the tumor microenvironment.

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) released its Q3 2021 financial results, reporting a net loss of $1.6 million, down from $2.0 million in Q3 2020. Total operating expenses rose to $1.8 million, driven by a $0.3 million decline in R&D costs and a $0.5 million increase in general and administrative expenses. The company secured $1.5 million in debt financing for a joint venture with Golden Mountain Partners (GMP) to advance its product pipeline, including OT-101. The promising efficacy signals from OT-101 for COVID-19 treatment were highlighted, with a reduction in mortality rates during trials.

Oncotelic Therapeutics (OTCQB:OTLC) announced positive results from its COVID-19 trial (C001) for OT-101, a first-in-class anti-TGF-β therapeutic. The trial met its safety and efficacy endpoints, showing a 4.5% mortality rate for OT-101 compared to 20% for placebo. Additionally, it achieved a viral load knockdown of 89% versus 67% for placebo, and improved survival for critical patients from 4 days (placebo) to 14 days (OT-101). These results support the further development of OT-101 for severe respiratory infections, including COVID-19.

Oncotelic Therapeutics (OTCQB:OTLC) announced progress in its ongoing OT-101/IL-2 combination trial, successfully completing the safety evaluation phase. This advancement allows for expansion into Phase 2 clinical trials and increased dosage levels. OT-101 is a first-in-class TGF-β targeting therapeutic, showing promising safety and efficacy in patients with advanced solid tumors. The optimal dosage from prior trials is being explored further. Results from this trial could enhance cure rates for metastatic kidney cancer and melanoma.

Oncotelic Therapeutics (OTCQB:OTLC) provided an update on its Phase 2 C001 Covid Study and the OT-101-ONC program, focusing on TGF-β immunotherapy for oncology and virology. Data lock for the Covid study was completed, with top-line results pending data analysis. The OT-101-ONC program has expanded to target cancers like mesothelioma and pancreatic cancer, supported by partnerships with leading pharmaceutical companies. Ongoing clinical trials with IL-2 and PD-1 inhibitors are expected to advance in 2021-2022. Oncotelic aims to enhance treatment outcomes for cancer patients.